Parexel in Medical Affairs Company buyout deal, lowers forecast

Parexel has acquired contract medical affairs services provider The Medical Affairs Company (TMAC) as it looks to bolster its outsourced healthcare specialist offering.

The deal, financial terms of which were not disclosed, sees the major CRO gain complete access to the Georgia-based TMAC and its outsourced medical affairs services to biopharma and the medical device industries.

The decade-old, 200-employee strong company works as a full-service contract medical organization and uses what are known as medical science liaisons (MSLs), as well as clinical nurse educator support services, across a host of areas from medical affairs consulting and med comms support, to direct placement services.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Parexel said in a statement: “Outsourcing medical affairs services presents a compelling option for biopharmaceutical companies as a way to reduce fixed costs. The increasingly complex nature of new products, and the need to demonstrate the therapeutic and reimbursement value of a product, is creating demand for credentialed healthcare professionals, such as MSLs, to lead clinically robust dialogues with key medical stakeholders on a peer-to-peer level.”

Though being bought out, Parexel says its new unit will work independently under its old management, although under the CRO’s umbrella.

This also comes as the company announces its Q2 results which saw its service revenue up more than 3% to $534.4 million, with backlog increased 8.4% year-over-year to $5.94 billion.

But the CRO has seen headwinds. Josef von Rickenbach, chairman and CEO, said: “Revenue growth in the quarter was relatively modest mainly due to the lingering impact of cancellations in prior periods, continuing slower backlog conversion due to increasing clinical trial complexity, and revenue delays from recent awards.

"As we expect recent strong new business awards to contribute less near-term revenue than we had anticipated, we are lowering our forecast for fiscal year 2017 revenue and diluted EPS."


Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.